Immunovia is hosting a webcast offering an opportunity to learn more about the positive clinical validation of its next-generation pancreatic cancer test.

Lund, Sweden, December 16, 2024 /PRNewswire/ — immunity A pancreatic cancer diagnostic company (IMMNOV: Nasdaq Stockholm) announced positive results from clinical validation of a next-generation pancreatic cancer screening method. December 9, 2024. As a follow up, immunity We will be hosting a webcast. Tuesday, December 17th to 3:00 PM (CET).

Jeff BorcherdingCEO, Norma Alonzo PalmaPhD, Clinical Vice President and medical treatment (TASE:) work and Lisa Ford (NYSE:)PhD, the lab director, will present additional details about the findings and implications of the study. doctor. Amy LucasDepartment of Gastroenterology and Hepatology Mount Sinai and professor Medicine Icahn School of MedicineWe will be joining the webcast to share our perspectives on our findings. The webcast will be in English and will provide attendees with the opportunity to ask questions. Welcome to membership. See below for more details.

Webcast link: https://link.edgepilot.com/s/e8dd2ee9/T5WEGMPm6EqzxajKwPwQbw?u=https://creo-live.creomediamanager.com/dd81645b-30e0-45e1-af83-75a059fcba71

A recording of the presentation is available at: immunity Website.

For more information, please contact:
Karin Almqvist Rivendal
chief financial officer
karin.almqvist.liwendahl@immunovia.com

immunity In short

immunity AB It is a diagnostic company whose mission is to increase the survival rate of pancreatic cancer patients through early detection. immunity is focused on the development and commercialization of simple blood-based tests that detect proteins and antibodies indicative of the development of pancreatic cancer in high-risk individuals.

immunity We collaborate and engage with health care providers, leading experts, and patient advocacy groups to provide testing to individuals at high risk for pancreatic cancer.

USA The pancreatic cancer diagnosis market is the world’s largest. The company estimates as follows: USA1.8 million individuals are at high risk for pancreatic cancer and would benefit from annual surveillance testing.

immunity The stock (IMMNOV) is listed on Nasdaq Stockholm. For more information, visit www.immunovia.com.

This information is provided by Cision http://news.cision.com.

https://news.cision.com/immunovia-ab/r/immunovia-to-host-a-webcast-with-the-opportunity-to-learn-more-about-the-positive-clinical-validatio,c4082507

You can download the following files: